March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
5 citations
,
July 2020 in “Recent patents on inflammation & allergy drug discovery” Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
February 2026 in “Acta Dermato Venereologica” Alopecia areata causes significant financial strain and dissatisfaction with treatment in Norway and Sweden.
September 2025 in “International Journal of Science and Research (IJSR)” Stress causes hair loss by disrupting hair growth cycles, and combining medical and cosmetic treatments can help manage it.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
August 2024 in “JAAD Case Reports” Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
59 citations
,
September 2021 in “Journal of Allergy and Clinical Immunology” Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.
13 citations
,
September 2018 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
5 citations
,
December 2024 in “Anais Brasileiros de Dermatologia” Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
1 citations
,
January 2025 in “Genes & Diseases” Understanding T cells and signaling pathways can lead to better treatments for hair loss.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Fzd2 is important for skin and hair development through various signaling ways.
August 2023 in “Journal of The American Academy of Dermatology” Early treatment is key for permanent hair loss disorders, with options ranging from medications and phototherapy to immunomodulators and antibiotics, depending on severity and type.
May 2023 in “Elsevier eBooks” Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.
November 2025 in “Journal of Investigative Dermatology” Combination therapy, including JAK inhibitors, effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.
July 2024 in “Journal of Investigative Dermatology” Topical corticosteroids are recommended first for treating pediatric alopecia areata due to safety and ease of use.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” IL-15 promotes hair growth and protects hair follicles.
June 2022 in “Value in Health” Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
July 2025 in “Skin Appendage Disorders” Improving education, insurance, and support can help scarring alopecia patients access better care.